Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies.

Al-Zebeeby A, Vogler M, Milani M, Richards C, Alotibi A, Greaves G, Dyer MJS, Cohen GM, Varadarajan S.

Haematologica. 2019 May;104(5):1016-1025. doi: 10.3324/haematol.2018.204701. Epub 2018 Nov 22.

2.

Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations.

Henz K, Al-Zebeeby A, Basoglu M, Fulda S, Cohen GM, Varadarajan S, Vogler M.

Biol Chem. 2019 Jan 28;400(2):181-185. doi: 10.1515/hsz-2018-0233.

PMID:
29924730

Supplemental Content

Loading ...
Support Center